CERVOMED INC. - COMMON STOCK

9.6000

22-November-24 16:44:58

15 minutes delayed

Stocks

+0.0200

+0.21%

Today's range

9.3000 - 10.3000

ISIN

N/A

Source

NASDAQ

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

01 Apr 2024 08:00:00 By Nasdaq GlobeNewswire
CervoMed to Participate in Upcoming Investor Conferences

28 Mar 2024 16:05:00 By Nasdaq GlobeNewswire
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

28 Mar 2024 08:30:00 By Nasdaq GlobeNewswire
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
CervoMed to Participate in the BIO CEO and Investor Conference

21 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

12 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

07 Feb 2024 08:30:00 By Nasdaq GlobeNewswire
CervoMed to Participate in the Emerging Growth Conference 67

05 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
CervoMed to Participate in the Emerging Growth Conference 66

05 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.